[1]张毅),Michael Nishimura).肿瘤的细胞免疫治疗[J].郑州大学学报(医学版),2011,(02):165.
点击复制

肿瘤的细胞免疫治疗()
分享到:

《郑州大学学报(医学版)》[ISSN:1671-6825/CN:41-1340/R]

卷:
期数:
2011年02期
页码:
165
栏目:
特约述评
出版日期:
2011-03-20

文章信息/Info

作者:
张毅12)Michael Nishimura3)
1)郑州大学第一附属医院生物细胞治疗中心 郑州 450052
2)郑州大学生物工程系 郑州 450001
3)美国南卡罗来纳州医科大学外科学 查理斯顿 29425
关键词:
肿瘤细胞免疫治疗肿瘤抗原肿瘤浸润性淋巴细胞
文献标志码:
A
摘要:

张毅,男,1964年4月生,郑州大学第一附属医院生物细胞治疗中心主任,细胞生物学专业河南省特聘教授。河南医科大学医学学士,同济医科大学医学硕士,比利时鲁汶大学肿瘤免疫学博士, 路德维格癌症研究所布鲁塞尔分所博士后,美国芝加哥大学研究助理教授, 美国南卡罗来纳医科大学Tenuretrack助理教授。自1999年开始先后到比利时和美国留学,2010年5月回国工作。从事癌症的生物细胞治疗研究20余年。自20世纪90年代初,先后在河南医科大学和北京大学人民医院从事LAK和CIK细胞的临床应用和试验研究。在国外的主要研究领域是肿瘤抗原的鉴定、肿瘤疫苗的临床应用和免疫检测、肿瘤特异性淋巴细胞的克隆和鉴定、肿瘤高亲和力T细胞受体的鉴定和应用以及肿瘤干细胞与免疫关系等。发表学术论文60余篇,其中SCI收录20余篇,被引用450多次。先后参与和承担了国家“973”攻关课题、欧盟科研计划、美国癌症研究所基金、美国癌症协会基金以及美国国立卫生研究院课题等20余项课题。现为美国癌症研究会、美国免疫学家协会和美国科学促进会会员。目前的主要研究方向为肿瘤免疫学、肿瘤干细胞和生物细胞治疗。

Michael Nishimura,男,1959年12月生,1980年获美国马里兰大学生物学学士学位,1984年获马里兰大学遗传学硕士学位,1989年获马里兰大学肿瘤免疫学博士学位,1989年至1992年在加州理工大学分子免疫学研究室作博士后研究。1992年到2000年,作为高级研究员在美国国立卫生研究院从事肿瘤免疫治疗的研究。2000年任芝加哥大学外科肿瘤研究室副教授及主任。2006年9月至今,任南卡罗来纳州医科大学外科学系副主席和教授。在美国国立卫生研究院工作期间,参与了肿瘤特异性过继免疫治疗方法的制定和临床应用工作。在20世纪90年代中期率先提出了T细胞受体基因转染治疗癌症的设想,并对此进行了多年的研究。2006年和丹麦的科学家一起,率先报道了T细胞受体基因转染治疗癌症的临床结果。撰写专著多部,并在国际最著名的刊物包括《Science》、《Nature》、《Immunology》、《Immunity》、《PNAS》、《PLoS One》和《Cancer Research》等发表论文近80篇。担任20多种国际刊物的编委或审稿人。应邀参加了100多次各种基金的评选委员会,多次担任美国国立卫生研究院基金评选委员会和美国癌症基金会肿瘤免疫学项目评审组组长或负责人。应邀到全球各地的学术机构演讲90多次,担任国际大会的专题主席30多次;拥有多项肿瘤生物治疗领域的专利。目前的研究方向是完善T细胞受体基因转染治疗癌症的技术和方法,并把现有的研究成果更好地转化到临床应用中。

参考文献/References:

[1]Coley WB.The treatment of malignant tumors by repeated inoculums of erysipelas[J].Am J Med Sci,1893,105:487
[2]Geldmacher A,Freier A,Losch FO,et al.Therapeutic vaccination for cancer immunotherapy:antigen selection and clinical responses[J].Hum Vaccin,2011(7)[Epub ahead of print]
[3]Vergati M, Intrivici C, Huen NY,et al. Strategies for cancer vaccine development[J].J Biomed Biotechnol,2010.Epub 2010 Jul 11.
[4]Koos D,Josephs SF,Alexandrescu DT,et al.Tumor vaccines in 2010: need for integration[J].Cell Immunol,2010,263(2):138
[5]Drake CG.Prostate cancer as a model for tumour immunotherapy[J].Nat Rev Immunol,2010,10(8):580
[6]Mule JJ,Shu S,Schwarz SL,et al.Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin2[J].Science,1984,225(4669):1487
[7]Kimura H,Yamaguchi Y.A phaseⅢrandomized study of interleukin2 lymphokineactivated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinonm[J].Cancer,1997,80(1):42
[8]Kimura H,Yamaguchi Y.Adjuvant chemoimmunotherapy after curative resection of Stage Ⅱ and ⅢA primary lung cancer[J].Lung Cancer,1996,14(2/3):301
[9]Rosenberg SA,Lotze MT,Yang JC,et al.Prospective randomized trial of highdose interleukin2 alone or in conjunction with lymphokineactivated killer cells for the treatment of patients with advanced cancer[J].J Natl Cancer Inst,1993,85(8):622
[10]SchmidtWolf IG,Negrin RS,Kiem HP,et al.Use of a SCID mouse/human lymphoma model to evaluate cytokineinduced killer cells with potent antitumor cell activity[J].J Exp Med,1991,174(1):139
[11]Wu C,Jiang J,Shi L,et al. Prospective study of chemotherapy in combination with cytokineinduced killer cells in patients suffering from advanced nonsmall cell lung cancer[J].Anticancer Res,2008,28(6B):3997
[12]Niu Q,Wang W,Li Y,et al.Cord bloodderived cytokineinduced killer cells biotherapy combined with secondline chemotherapy in the treatment of advanced solid malignancies[J].Int Immunopharmacol,2011.[Epub ahead of print]
[13]Linn YC,Hui KM.Cytokineinduced NKlike T cells:from bench to bedside[J].J Biomed Biotechnol,2010(2010):435745
[14]Wang S,Du W,Zhang H,et al.Biological characteristics and antitumor activity of CIK cells activated by recombinant human fibronectin for human lung cancer cell lines in vitro[J].Zhongguo Fei Ai Za Zhi,2010,13(4):277
[15]Verneris MR,Konacker M,Mailnder V,et al.Resistance of ex vivo expanded CD3+ CD56+ T cells to Fasmediated apoptosis[J].Cancer Immunol Immunother,2000,49(6):335
[16]Rosenberg SA,Spiess P,Lafreniere R.A new approach to the adoptive immunotherapy of cancer with tumor infiltrating lymphocytes[J].Science,1986,233(4770):1318
[17]Schwartzentruber DJ,Topalian SL,Mancini M, et al. Specific release of granulocytemacrophage colonystimulating factor, tumor necrosis factoralpha, and IFNgamma by human tumorinfiltrating lymphocytes after autologous tumor stimulation[J]. J Immunol, 1991,146(10):3674
[18]Topalian SL,Solomon D, Rosenberg SA,et al.Tumorspecific cytolysis by lymphocytes infiltrating human melanomas[J].J Immunol,1989,142(10):3714
[19]Yannelli JR,Hyatt C, McConnell S, et al. Growth of tumorinfiltrating lymphocytes from human solid cancers: summary of a 5year experience[J].Int J Cancer,1996,65(4):413
[20]Kradin RL,Boyle LA,Preffer FI,et al.Tumor derived interleukin2 dependent lymphocytes in adoptive immunotherapy of lung cancer[J].Cancer Immunol Immunother,1987,24(1):76
[21]Dudley ME,Wunderlich JR,Robbins PF,et al.Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes[J].Science,2002,298(5594):850
[22]Dudley ME,Wunderlich JR,Yang JC,et al.Adoptive cell transfer therapy following nonmyeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma[J].J Clin Oncol,2005,23(10):2346
[23]Goff SL,Smith FO,Klapper JA,et al.Tumor infiltrating lymphocyte therapy for metastatic melanoma:analysis of tumors resected for TIL[J].J Immunother,2010,33(8):840
[24]Kilic A,Landreneau RJ,Luketich JD,et al.Density of tumorinfiltrating lymphocytes correlates with disease recurrence and survival in patients with large nonsmallcell lung cancer tumors[J].J Surg Res,2009,23(1):1
[25]Ruffini E, Asioli S, Filosso PL,et al.Clinical significance of tumorinfiltrating lymphocytes in lung neoplasms[J].Ann Thorac Surg,2009,87(2):365
[26]Clay TM,Custer MC,Sachs J,et al.Efficient transfer of a tumor antigenreactive TCR to human peripheral blood lymphocytes confers antitumor reactivity[J].J Immunol,163(1):507
[27]Bobisse S,Rondina M,Merlo A,et al.Reprogramming T lymphocytes for melanoma adoptive immunotherapy by Tcell receptor gene transfer with lentiviral vectors[J].Cancer Res,2009,69(24):9385
[28]Roszkowski JJ,Lyons GE,Kast WM,et al.Simultaneous generation of CD8+ and CD4+ melanoma reactive T cells by retroviral mediated transfer of a single Tcell receptor[J].Cancer Res,2005,65(4):1570
[29]Frankel TL,Burns WR,Peng PD,et al.Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinase[J].J Immunol,2010,184(11):5988
[30]Kessels HW,Wolkers MC,van den Boom MD,et al. Immunotherapy through TCR gene transfer[J].Nat Immunol,2001,2(10):957
[31]Koya RC,Mok S,CominAnduix B,et al.Kinetic phases of distribution and tumor targeting by T cell receptor engineered lymphocytes inducing robust antitumor responses[J].Proc Natl Acad Sci USA,2010,107(32):14286
[32]Duval L,Schmidt H, Kaltoft K, et al.Adoptive transfer of allogeneic cytotoxic T lymphocytes equipped with a HLAA2 restricted MART1 Tcell receptor:a phase Ⅰ trial in metastatic melanoma[J].Clin Cancer Res, 2006,12(4):1229
[33]Morgan RA, Dudley ME, Wunderlich JR,et al. Cancer regression in patients after transfer of genetically engineered lymphocytes[J].Science,2006,314(5796):126
[34]Johnson LA, Morgan RA, Dudley ME,et al. Gene therapy with human and mouse Tcell receptors mediates cancer regression and targets normal tissues expressing cognate antigen[J].Blood,2009,114(3):535
[35]van der Bruggen P,Traversari C,Chomez P,et al.A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma[J].Science,1991,254(5038):1643
[36]Warren EH,Fujii N,Akatsuka Y,et al.Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens[J].Blood,2010,115(19):3869
[37]Khammari A,Labarrire N,Vignard V,et al.Treatment of metastatic melanoma with autologous MelanA/MART1specific cytotoxic T lymphocyte clones[J].J Invest Dermatol,2009,129(12):2835
[38]Hunder NN,Wallen H,Cao J,et al.Treatment of metastatic melanoma with autologous CD4+ T cells against NYESO1[J].N Engl J Med, 2008,358(25):2698
[39]Vignard V,Lemercier B,Lim A,et al.Adoptive transfer of tumorreactive MelanAspecific CTL clones in melanoma patients is followed by increased frequencies of additional MelanAspecific T cells[J]. J Immunol, 2005, 175(7): 4797
[40]Li Y,Yee C. IL21 mediated Foxp3 suppression leads to enhanced generation of antigenspecific CD8+ cytotoxic T lymphocytes[J] .Blood,2008,111(1): 229
[41]CasalegnoGarduo R,Schmitt A, Yao J, et al.Multimer technologies for detection and adoptive transfer of antigenspecific T cells[J].Cancer Immunol Immunother,2010,59(2):195

相似文献/References:

[1]岳松伟,周悦,郭华,等.消化系统神经内分泌癌的CT表现及病理特征[J].郑州大学学报(医学版),2012,(03):419.
[2]冯悦静),魏小玲),尤爱国),等.肺癌患者血清中DNMT1、DNMT3a、DNMT3b和HDAC1蛋白的表达*[J].郑州大学学报(医学版),2014,(03):323.
 FENG Yuejing,WEI Xiaoling,YOU Aiguo,et al.Expressions of DNMT1,DNMT3a,DNMT3b and HDAC1 in serum from patients with lung cancer[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2014,(02):323.
[3]王海楠),祁元明)#,高艳锋),等.河南省肿瘤、慢性丙型肝炎、白癜风患者HLAA2的分布*[J].郑州大学学报(医学版),2014,(03):349.
 WANG Hainan),QI Yuanming),GAO Yanfeng),et al.Frequencies of HLAA2 among patients with tumors,chronic hepatitis C and vitiligo in Henan Province[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2014,(02):349.

更新日期/Last Update: